Dergiler / Dicle Tıp Dergisi / 2015 / Cilt: 42 Sayı: 2

Adalimumab tedavisi alan romatoid artritli hastada seksüel disfonksiyon

-

Sayfa
—
Yayın Tarihi
2015-07-09
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Key words: Rheumatoid arthritis, adalimumab, sexual dysfunction

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Rheumatoid arthritis (RA) is a chronic, systemic and inflammatory disease characterized by symmetric polyarthritis and arthralgia, morning stiffness, fatigue and rheumatoid nodules.
📊
Temel Bulgular & Veri:Both women and men with RA suffer from decreased sexual function.
💡
Sonuç & Katkı:Key words: Rheumatoid arthritis, adalimumab, sexual dysfunction
🔬Tür:Makale
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Romatoid artrit · adalimumab · seksüel disfonksiyon

Özet

Rheumatoid arthritis (RA) is a chronic, systemic and inflammatory disease characterized by symmetric polyarthritis and arthralgia, morning stiffness, fatigue and rheumatoid nodules. Multifactorial etiology such as genetic, infectious, hormonal or environmental factors contribute to disease susceptibility. However, clear etiology is not still defined. Both women and men with RA suffer from decreased sexual function. Also, many factors include disease activity, medications or psychological disorders can affect sexual health in a patients with RA. Sexual health is important for human life. However, often overlooked is the association between RA and sexual problems in clinical practice. We present a case of sexual dysfunction developing after adalimumab treatment in a man patient with RA. Key words: Rheumatoid arthritis, adalimumab, sexual dysfunction

Abstract

Rheumatoid arthritis (RA) is a chronic, systemic and inflammatory disease characterized by symmetric polyarthritis and arthralgia, morning stiffness, fatigue and rheumatoid nodules. Multifactorial etiology such as genetic, infectious, hormonal or environmental factors contribute to disease susceptibility. However, clear etiology is not still defined. Both women and men with RA suffer from decreased sexual function. Also, many factors include disease activity, medications or psychological disorders can affect sexual health in a patients with RA. Sexual health is important for human life. However, often overlooked is the association between RA and sexual problems in clinical practice. We present a case of sexual dysfunction developing after adalimumab treatment in a man patient with RA

🔖

Bu Makaleye Atıf Yap

Yazmalar, L., Sarıyıldız, M., Batmaz, İ. (2015). Adalimumab tedavisi alan romatoid artritli hastada seksüel disfonksiyon. Dicle Tıp Dergisi, Cilt: 42 Sayı: 2. https://doi.org/10.5798/diclemedj.0921.2015.02.0570

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (16)

  1. Yazmalar L, Ediz L, Alpayci M, et al. Seasonal disease activity and serum vitamin D levels in rheumatoid arthritis, ankylosing spondylitis and osteoarthritis. Afr Health Sci;13:47-55.
  2. Batmaz I, Sarıyıldız MA, Dilek B, et al. Sexuality of men
  3. with fibromyalgia: what are the factors that cause sexual
  4. dysfunction? Rheumatol Int 2013;33:1265-1270.
  5. Van Berlo WT, van de Wiel HB, Taal E, et al. Sexual functioning of people with rheumatoid arthritis: a multicenter
  6. study. Clin Rheumatol 2007;26:30-38.
  7. Areskoug-Josefsson K, Oberg U. A literature review of the
  8. sexual health of women with rheumatoid arthritis. Musculoskeletal Care 2009;7:219-226.
  9. El Miedany Y, El Gaafary M, El Aroussy N, et al. Sexual
  10. dysfunction in rheumatoid arthritis patients: arthritis and
  11. beyond. Clin Rheumatol 2012;3:601-606.
  12. Oh JS, Heo HM, Kim YG, et al. The effect of anti-tumor necrosis factor agents on sexual dysfunction in male patients
  13. with ankylosing spondylitis: a pilot study. Int J Impot Res;21:372-375.
  14. Kreitenberg AJ, Ortiz EC, Arkfeld DG. Priapism after tumor
  15. necrosis factor alpha inhibitor use. Clin Rheumatol 2015;
  16. DOI 10.1007/s10067-014-2858-x.